RAP2A

Across TCGA pan-cancer cohorts, RAP2A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RAP2A data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RAP2A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RAP2A expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

LUAD, LSCC, and HNSC are the cancer types where RAP2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.296	0.816	<.001	65	view →
LSCC	DFS	Quartile	All	0.649	0.906	.004	19	view →
HNSC	DFS	Median	II,III,IV	0.981	0.911	.010	8	view →
GBM	DFS	Median	All	0.832	0.664	.011	2	view →
CCRCC	DFS	Tertile	All	0.794	0.598	.047	1	view →
PDAC	OS	Median	III,IV	1.000	0.526	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RAP2A–LUAD (DFS)

Open the LUAD breakdown →